Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
dianosic logo — "Smartly designed for you"

dianosic

"Smartly designed for you"

Founded 2017 France France 13 employees Seed Total: $6.20M Biotechnology, Medical Devices +1

General Information

Company Name dianosic
Founded Year 2017
Location France France
Employees 13
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Seed
Business Model B2B, B2D, D2C
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with dianosic. To contact dianosic, visit dianosic.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does dianosic compare?

A PDF of dianosic and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting dianosic soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About dianosic

Dianosic, founded in 2017, operates at the intersection of Biotechnology, Medical Devices, and Pharmaceutical industries. Headquartered in France, the company is embroiled in revolutionizing patient adherence to medication through its innovative sustained intranasal drug delivery solutions, targeting respiratory and chronic central nervous system diseases.

Dianosic's mission is to alleviate chronic diseases, beginning with chronic allergic rhinitis and rhinosinusitis, where compliance and treatment effectiveness are major concerns for over 85% and up to 25% of patients, respectively. Their collaboration with healthcare specialists in otorhinolaryngology and neurosurgery fosters solutions that enhance treatment efficacy and ease-of-use for patients and physicians alike.

Their flagship platform, ARIS, utilizes a proprietary drug-eluting, long-term resorbable polymer, encapsulating its motto, "Smartly designed for you," by offering "insert and forget" solutions. Their recent €4.70M Seed Round investment round, backed by Bpifrance, Fondation Force, and WiSEED, underscores investor confidence in their trajectory.

Business keywords: Drug Delivery Solutions, Chronic Disease Management, Respiratory Diseases, Central Nervous System Diseases, Patient Adherence, Medical Compliance Solutions, ENT Conditions, Intranasal Drug Delivery, Polymer Expertise, Healthcare Innovation, Treatment Paradigms, Medical Device Development, Biotech Innovations, Innovative Healthcare Solutions

Services & Products

Development of Transformative Intranasal Solutions
ARIS Platform for Chronic Rhinitis and Rhinosinusitis
Non-Surgical Patient Adherence Solutions
Intranasal Drug Delivery to CNS

Target Customers

Patients with Chronic Rhinitis Patients with Chronic Rhinosinusitis Healthcare Professionals Medical Researchers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €4.70M 3
Bpifrance Fondation Force
Bpifrance, Fondation Force +1
06 Feb 2023
Seed Round €1.50M 4
Bpifrance Banque Populaire Rives de Paris
Bpifrance, Banque Populaire Rives de Paris +2
14 Apr 2020

dianosic Alternatives & Competitors

View All Alternatives
dianosic vs
UCB
UCB Belgium

We’re #TeamUCB, a global biopharmaceutical company. 💙 Inspired by patients 🔬 Driven by science

IPO
15278 employees
Biotechnology, Health Care
dianosic vs
Emalex Biosciences
Emalex Biosciences United States

Improving people's lives impacted by central nervous system disorders through meaningful scientific...

Series D
54 employees
Biopharma, Biotechnology
dianosic vs
Novoron Bioscience
Novoron Bioscience United States

Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spi...

Seed
17 employees
Biopharma, Biotechnology
View all alternatives

FAQ About dianosic

"Smartly designed for you"
dianosic was founded in 2017.
dianosic is headquartered in France.
dianosic operates in Biotechnology, Medical Devices and Pharmaceutical. Its work centres on Drug Delivery Solutions, Chronic Disease Management, Respiratory Diseases and Central Nervous System Diseases. Its customers include Patients with Chronic Rhinitis, Patients with Chronic Rhinosinusitis and Healthcare Professionals.
dianosic has a B2B, B2D and D2C business model. Its revenue comes from Product Sales, Licensing and Service Fee.
dianosic has approximately 13 employees.
dianosic has completed 2 funding rounds, raising a total of $6.20M. The latest funding stage is Seed.
dianosic offers: Development of Transformative Intranasal Solutions, ARIS Platform for Chronic Rhinitis and Rhinosinusitis, Non-Surgical Patient Adherence Solutions, Intranasal Drug Delivery to CNS.
Top alternatives and competitors to dianosic include UCB, Emalex Biosciences, Novoron Bioscience, Novo Nordisk, Yaqrit. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
dianosic and UCB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for dianosic, https://bouncewatch.com/company/dianosic, updated 24 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout